serving only as common aspirations. "If the statements stay at this general level they're not going to be Earth-shattering, " says Flanagan.
But behind the scenes, agency heads were sharing tips and experience. Oliva, for example, says that his agency is coming under government pressure to focus on practical problems, and is rethinking its evaluation systems to include indicators that value innovation. "It's nice to see how other countries are dealing with these indicators, " he says.
Before the next major GRC meeting -in Berlin in 2013, by which time the council is expected to have almost 100 members -the group will discuss research integrity and open access to scientific data and published research. The basic principles of research integrity have already been laid down in international guidelines such as the Singapore Statement, agreed by researchers and funders in 2010. But Matthias Kleiner, who heads the DFG, Germany's main research-funding agency, says that the GRC could discuss practical questions such as how to tackle the problem of researchers being sanctioned for misconduct in one country, but continuing their research freely elsewhere.
Agreeing 
PLAN FOR THE FUTURE
Craft says that she was "thrilled" to be funded for a larger, follow-on trial. But like many in the field, she worries that the national Alzheimer's plan is under-funded in the long term. "We all would like to believe that this is an important moment, " she says, "but we need to see follow-up in order to be truly convinced that this will provide an ongoing, coherent effort to address Alzheimer's disease. " On 15 May, an advisory council to the US Department of Health and Human Services recommended that the government quickly ramp up research spending to $2 billion per year if it wants to meet its goal of developing effective treatments and preventive measures by 2025. That would mean a quadrupling of the NIH's current spending on Alzheimer's research.
"We really have all the pieces we need to move forward in the development of effective therapeutics, " says Paul Aisen, a neuroscientist at the University of California, San Diego, and director of the Alzheimer's Disease Cooperative Study -a 21-yearold programme of government-funded clinical studies aimed at developing Alzheimer's treatments. "The missing piece right now is the money. "
The first test of a follow-up will come later this year as Congress wrestles over the administration's 2013 budget request for the NIH. Included in the request is an additional $80 million for Alzheimer's research. Proponents say that a failure to adequately fund research today will only lead to higher costs later.
"We're in trouble now, " says Aisen, "but in another 20 years, if things don't change, we're going to be in a dreadful situation. 
GLOBAL SCIENCE
The proportion of research papers from international collaborations is increasing in many regions. 
